[citation needed] In 2021 Bach joined DELFI Diagnostics, a liquid biopsy cancer screening company, as its Chief Medical Officer in 2021.

The New York Times piece by Bach was discussed in a 60 Minutes segment highlighting the rising cost of cancer drugs.

Additionally, Bach co-authored a paper published in the American Medical Association in which he described possible value-based drug pricing approaches in the United States.

Along with research collaborators, he has published evidence that black Medicare beneficiaries with lung cancer do not receive as high quality care as white patients.

[15][16] In 2016 Bach led an analysis that demonstrated that pharmaceutical companies were increasing revenues Notable policy His lay press contributions have included op-eds on topics such as medical school tuition funding,[17] setting physician reimbursement based on market forces,[18] and why cancer screening recommendations are often not followed.